Fig. 4

Combination of TRAIL and leptomycin B synergistically induces extrinsic and intrinsic apoptotic programs in a p53-independent manner. a ECC-1 and A2780CP cell lines were treated with leptomycin B (20 nM), cisplatin (10 μM), TRAIL (100 ng/mL) or a combination of leptomycin B with cisplatin or TRAIL for 24 h. Western blot was performed using relevant antibodies and β-Actin was used as a loading control. Results shown are representative of three independent experiments. b ECC-1 and A2780CP cell lines were treated with leptomycin B (20 nM), TRAIL (100 ng/mL) or a combination of leptomycin B with TRAIL for 24 h. Western blot was performed using relevant antibodies and β-Actin was used as a loading control. Results shown are representative of three independent experiments. c Immunofluorescence experiments were conducted in order to determine the effect of the previous treatments on p53 subcellular localization d. ECC-1 and A2780CP cell lines were reverse transfected with a p53 siRNA and then treated a combination of leptomycin B (20 nM) and TRAIL (100 ng/mL) for 24 h. Western blot was performed using relevant antibodies and β-Actin was used as a loading control. Results shown are representative of three independent experiments. e Kaplan Meier plot showing the significantly increased survival rate found in ovarian cancer patients presenting high level of DR5 receptors; obtained from dataset GSE9891/209294_x_at